WA-SPIE
11.1.2022 18:39:07 CET | Business Wire | Press release
The Awards Committee of SPIE, the international society for optics and photonics , today announced the recipients of its prestigious annual awards . Honoring transformative advancements in multiple areas — including medicine, astronomy, lithography, optical metrology, optical design, and community leadership — the Society's awards recognize technical accomplishments as well as committed service to SPIE and support of its organizational mission.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005942/en/
SPIE Gold Medal: Michael Berns
In recognition of his work in bioengineering research and his distinguished career that brought together engineers, physicists, biologists, and physicians to collaborate on ground-breaking discoveries and innovations.
SPIE President's Award: Tuan Vo-Dinh
In recognition of his outstanding and extensive role in SPIE conference leadership, in disparate technical areas, and for his mentorship of early investigators as well as peers.
SPIE Directors' Award: Julie Bentley
In recognition of her outstanding service to the Society in extraordinary ways, including authorship, course instruction, conference program leadership, committee membership, and service on the Board of Directors.
SPIE Mozi Award: Thomas W. Ebbesen
In recognition of his phenomenal contributions to the field of nano-optics, especially the extraordinary optical transmission through sub-wavelength hole arrays.
SPIE Britton Chance Award in Biomedical Optics: Bruce Tromberg
In recognition of his high-impact translational research and overall leadership in the development of biophotonic technologies for diagnostics and therapeutics.
SPIE Biophotonics Technology Innovator Award: Bert Müller
In recognition of his distinguished contributions to 2D and 3D imaging for the challenges of the 21st century, including cardiovascular and neurodegenerative diseases, bioinspired dental repair, and incontinence treatment.
SPIE Rudolf and Hilda Kingslake Award in Optical Design: Masato Shibuya
In recognition of his significant contributions to the development of optical design through the invention of phase-shift masks for photolithography, and for laying the foundations of imaging theory based on plane-wave expansions.
SPIE Harrison H. Barrett Award in Medical Imaging: Maryellen Giger
In recognition of her pioneering work in the fields of digital image formation, computer-aided diagnosis, radiomics, and radiogenomics.
SPIE Harold E. Edgerton Award in High-Speed Optics: Mona Jarrahi
In recognition of her pioneering contributions to plasmonic time-domain spectroscopy and imaging systems as well as their scientific and industrial applications.
SPIE Dennis Gabor Award in Diffractive Optics: Gabriel Popescu
In recognition of his groundbreaking contributions to holography and quantitative phase imaging for biomedical applications.
SPIE George W. Goddard Award in Space and Airborne Optics: Michelle Stephens
In recognition of her technical innovation, mentoring, and exceptional leadership in pursuit of space-based, fundamental measurements of the Earth and Sun, while reducing technological barriers and promoting standards for the advancement of space and airborne optics.
SPIE G. G. Stokes Award in Optical Polarization: Alex Vitkin
In recognition of his extensive contributions to tissue polarimetry, including advanced methodology developments for sensitive and robust Stokes and Mueller measurements; polarimetric computational and analytical platforms; and biomedical applications including cardiology, regenerative medicine, glucometry, and breast-cancer margin assessment.
SPIE Chandra S. Vikram Award in Optical Metrology: Jürgen Czarske
In recognition of his important contributions to computational laser metrology with paradigm changes in fluid dynamics, inspection, aerospace, communication, and biomedicine.
SPIE Frits Zernike Award for Microlithography: Harry J. Levinson
In recognition of his outstanding achievements contributing to our fundamental understanding of advanced lithography process control, especially in the concepts of Image-Log-Slope, Mask defect printability, and thin-film optics optimization.
SPIE Diversity Outreach Award: Qaisar Abbas Naqvi
In recognition of his inspirational attitude and dedication to students, helping transform the lives of women and men from traditionally under-recognized segments of society by supporting their pursuit of higher education and research in optics and related fields.
SPIE Maria Goeppert-Mayer Award in Photonics: Shin-Tson Wu
In recognition of his seminal contributions to display and photonic device technologies that led to widespread applications.
SPIE Maiman Laser Award: Bill Krupke
In recognition of his scientific, technical and community leadership, innovation, and numerous seminal results in laser science and technology.
SPIE Early Career Achievement Award — Academic Focus: Bhavin Shastri
In recognition of his pioneering efforts in the field of neuromorphic photonics and his contributions to interdisciplinary research across nanophotonics, unconventional computing, and silicon photonics that pushed the frontiers of machine learning.
SPIE Early Career Achievement Award — Industry/Government Focus: Lionel Clermont
In recognition of his significant achievements in the field of stray light control, particularly his work on the development of the ultrafast time-of-flight imaging characterization method.
SPIE Maria J. Yzuel Educator Award: Rajpal Sirohi
In recognition of his many years of service in the field of optics through leadership, capacity building, and outreach.
SPIE Aden and Marjorie Meinel Technology Achievement Award: Ge Wang
In recognition of his pioneering contributions in X-ray and optical molecular tomography, including their coupling for biomedical applications.
The complete listing of all SPIE awards and recipients is available here .
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005942/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom